CHMP Recommends Approval Of Olanzapine Long-acting Injection For Maintenance Treatment Of Schizophrenia In Europe The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Olanzapine Long-acting Injection (LAI), known in Europe by the trade name Zypadhera(TM), for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine, Eli Lilly and Company (LLY) announced today.
Source: www.medicalnewstoday.com
# posted by Network @ 2:00 PM
